timothy sykes logo

Stock News

ImmunityBio Expands Bladder Cancer Drug Reach Across Europe

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 2/23/2026, 9:19 am ET 2/23/2026, 9:19 am ET | 4 min 4 min read
ImmunityBio Expands Bladder Cancer Drug Reach Across Europe Thumbnail

ImmunityBio Inc.’s stocks have been trading up by 11.72 percent following encouraging FDA designations boosting investor confidence.

  • ImmunityBio is slated to widen its European commercial reach for its bladder cancer treatment through a partnership with Accord Healthcare, augmented by a new subsidiary in Dublin, Ireland.

  • In Saudi Arabia, ImmunityBio has solidified its commercial and regulatory presence, anticipating new expansions for its ANKTIVA drug with the backing of local authorities.

Candlestick Chart

Live Update At 09:18:44 EST: On Monday, February 23, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 11.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ImmunityBio’s recent performance highlights both strides and struggles. Its revenue charts show growth, with the latest reported revenue standing at $14.75M. However, profitability remains a glaring issue, reflected in a substantial negative EBIT margin of -319.5%. The company faces notable capital constraints, with high valuations—a price-to-sales ratio of 103.8x—posing challenges. Its financial balance shows a robust current ratio of 5.8, signaling strong liquidity.

Recent stock trends echo ImmunityBio’s mixed financial scenario. Daily shares traded reveal a fluctuating yet upward trajectory with March opening prices significantly higher than previous periods. The stock has experienced substantial increases, jumping nearly 30% following pivotal European endorsements. The day-to-day trading saw highs over $9.80 and lows just under $9.00, indicating strong interest amidst notable price movements.

Strength amidst Expansion and Challenges

ImmunityBio’s ongoing expansions manifest significant ambitions. The Medicine Agency’s green light to ANKTIVA marks a triumph, driving the company’s penetration into lucrative European markets. Tying up with Accord Healthcare fortifies the ability to distribute efficiently, reinforcing the company’s strategy to reach broader pockets of patients needing urgent cancer therapies.

Amid these successes, the firm also grapples with financial hurdles. Net income remains saddled by stark operational costs, and its path to achieving profit earnings involves hurdles over high debt servicing and capital limitations. Nevertheless, its strategic European foothold promises potential benefits—revamping revenue prospects in the intermediate to long haul.

Saudi initiatives align with ImmunityBio’s partnership strategy. They are not merely regulatory footholds; instead, they endorse the group’s broader plan to target regions with increasing oncology treatment demand, potentially bolstering future cash flows.

More Breaking News

Conclusion

In summary, ImmunityBio is positioned in an exciting yet precarious phase of growth. While tremendous opportunities arise across Europe and the MENA regions, the organization will need to maneuver its financial strategies shrewdly to leverage momentum. Industry stakeholders avidly watch as strategic partnerships potentially translate into improving bottom-line figures.

Traders have shown optimism via trading behavior, yet caution remains warranted. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” This insight is particularly relevant as ImmunityBio fortifies its international footprint, pacing financial health alongside expanding drug offerings will be critical in dictating future stock performances.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”